Brief: Grail Reports Full Results From Nhs-Galleri Trial Demonstrating Substantial Reduction In Stage Iv Cancer Diagnoses
30/05/2026 13:14
BRIEF-Grail Reports Full Results From Nhs-Galleri Trial Demonstrating Substantial Reduction In Stage Iv Cancer Diagnoses May 30 (Reuters) - Grail Inc GRAL.O:
GRAIL REPORTS FULL RESULTS FROM NHS-GALLERI TRIAL DEMONSTRATING SUBSTANTIAL REDUCTION IN STAGE IV CANCER DIAGNOSES AT 2026 ASCO ANNUAL MEETING
GRAIL - REPORTS NHS-GALLERI TRIAL SHOWS SUBSTANTIAL REDUCTION IN STAGE IV CANCER DIAGNOSES
GRAIL - GALLERI BLOOD TEST REDUCES STAGE IV DIAGNOSES BY 22% IN SECOND AND 26% IN THIRD ROUNDS
GRAIL INC - NO REDUCTION OBSERVED IN COMBINED PRIMARY ENDPOINT OF STAGE III/IV CANCERS IN AGGREGATE
Source text: ID:nPn6wRQXma
Further company coverage: GRAL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Grail
See all newsGrail rises as TD Cowen more than doubles PT on FDA, Medicare optimism
Grail's cancer blood test nears landmark FDA approval, but insurance coverage looms
U.S. RESEARCH ROUNDUP-Chevron, Mobility Global, Tesla
Street View: Grail cancer test's progress boosts prospects for multi-cancer detection market
NASDAQ RESUMED AT 07:05 AM